Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 225-234

  Moretti, Roberta M ^a   Mai, Stefania ^a   Marelli, Marina Montagnani ^a   Rizzi, Federica ^b   Bettuzzi, Saverio ^b   Limonta, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Cell invasion; Cell motility; Cytoskeleton; Nuclear clusterin; Prostate cancer

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; CLUSTERIN; COFILIN; GELATINASE A; LIM KINASE 1; UVOMORULIN; VIMENTIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ACTIN DEPOLYMERIZING FACTORS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CLUSTERIN; CYTOSKELETON; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIM KINASES; MALE; MATRIX METALLOPROTEINASE 2; MICROTUBULES; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; TRANSFECTION; VIMENTIN;

EID: 79956056648     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1030     Document Type: Article

References (58)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics 2009 CA Cancer J Clin 59: 225-249, 2009.
2. Javidan J, Deitch AD, Shi XB and De Vere White RW: The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest 23: 520-528, 2005. (Pubitemid 41463868)
3. Lee ECY and Tenniswood MPR: Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. J Cell Biochem 91: 662-670, 2004.
4. Garmey EG, Sartor O, Halabi S and Vogelzang NJ: Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 6: 118-122, 2008.
5. Di Lorenzo G, Buonerba C, Autorino R, De Placido S and Sternberg CN: Castration-resistant prostate cancer. Current and emerging treatment strategies. Drugs 70: 983-1000, 2010.
6. Harzstark AL and Small EJ: Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother 11: 937-945, 2010.
7. Jones SE and Jomary C: Clusterin. Int J Biochem Cell Biol 34: 427-431, 2002. (Pubitemid 34242756)
8. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W and Reichrath J: Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13: 12-19, 2006.
9. Purrello M, Bettuzzi S, Di Pietro C, Mirabile E, Di Blasi M, Rimini R Grzeschik KH, Ingletti C, Corti A and Sichel G: The gene for SP-40,40, human homolog of rat sulphated glycoprotein 2, rat clusterin, and testosterone- repressed prostate message 2, maps to chromosome 8. Genomics 10: 151-156, 1991.
10. Kirszbaum L, Bozas SE and Walker ID: SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 297: 70-76, 1992.
11. Rizzi F, Coletta M and Bettuzzi S: Clusterin (CLU): from one gene and two transcript to many proteins. Adv Cancer Res 104: 9-23, 2009.
12. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ and Boothman DA: Nuclear clusterin/XIP8, and X-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 97: 5907-5912, 2000. (Pubitemid 30367497)
13. Scaltriti M, Santamaria A, Paolucci R and Bettuzzi S: Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res 64: 6174-6182, 2004. (Pubitemid 39129419)
14. Reddy KB, Jin G, Karode MC, Harmony JA and Howe PH: Transforming ghrowth factor β (TGFβ)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35: 6157-6163, 1996.
15. Leskov K, Klokov D, Li J, Kinsella TJ and Boothman DA: Synthesis and functional analyses of nuclear clusterin: a cell death protein. J Biol Chem 278: 11590-11600, 2003. (Pubitemid 36792721)
16. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol 157: 393-399, 2000. (Pubitemid 30626904)
17. Pucci S, Bonanno E, Pichiorri F, Angeloni C and Spagnoli LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23: 2298-2304, 2004. (Pubitemid 38496784)
18. Yang G, Li XM and Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 19: 1342-1346, 2009.
19. Bi J, Guo AL, Lai YR, Li B, Zhong JM, Wu HQ, Xie Z, He YL, Lv ZL, Lau SH, Wang Q, Huang XH, Zhang LJ, Wen JM and Guan XY: Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarray. Neoplasma 57: 191-197, 2010.
20. Mazzarelli P, Pucci S and Spagnoli LG: CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype. Adv Cancer Res 105: 45-61, 2009.
21. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC and Wong KK: Clusterin interacts with Paclitaxel and confers Paclitaxel resistance in ovarian cancer. Neoplasia 10: 964-972, 2008.
22. Djeu JY and Wei S: Clusterin and chemoresistance. Adv Cancer Res 105: 77-92, 2009.
23. Wei L, Xue T, Wang J, Chen B, Lei Y, Huang Y and Xin X: Roles of clusterin in progression, chemoresistance and metastasis of human cancer. Int J Cancer 125: 791-806, 2009.
24. Watari H, Kanuma T, Ohta Y, Hassan M, Mitamura T, Hosaka M, Minegishi T and Sakuragi N: Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res 16: 345-352, 2010.
25. Dia VP and Mejia EG: Lunasin promotes apoptosis in human colon cancer cells by mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett 295: 44-53, 2010.
26. Rizzi F and Bettuzzi S: The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 17: R1-R17, 2010.
27. Steinberg J, Oyasu R Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM and Sensibar JA: Intracellular levels of SGP-2 (Clusterin) correlates with tumor grade in prostate cancer. Clin Cancer Res 3: 1707-1711, 1997. (Pubitemid 27444708)
28. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A and Bettuzzi S: Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 108: 23-30, 2004. (Pubitemid 37444439)
29. Rizzi F Belloni L, Crafa P, Lazzaretti M, Remondini D, Ferretti S, Cortellini P, Corti A and Bettuzzi S: A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS ONE 3: e3617, 2008.
30. Rizzi F and Bettuzzi S: Clusterin (CLU) and prostate cancer. Adv Cancer Res 105: 1-19, 2009.
31. Girard FR Byrne J, Downes M, Fanning D, Desgrandchamps F, Fitzpatrick JM and Watson RW: Detecting soluble Clusterin in in vitro and in vivo models of prostate cancer. Neoplasma 57: 488-493, 2010.
32. Miyake H, Muramaki M, Furukawa J, Kurahashi T and Fujisawa M: Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 75: 454-459, 2010.
33. Miyake H, Nelson C, Rennie PS and Gleave ME: Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60: 2547-2554, 2000. (Pubitemid 30262451)
34. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R and Wang CY: Clusterin inhibits apoptosis by interacting with activated bax. Nat Cell Biol 7: 909-915, 2005. (Pubitemid 41486292)
35. Sallman DA, Chen X, Zhong B, Gilvary D, Zhou J, Wei S and Djeu JY: Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 6: 2938-2947, 2007. (Pubitemid 350206772)
36. Ammar H and Closset JL: Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 283: 12851-12861, 2008.
37. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S and Djeu JY: Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 9: 1831-1841, 2010.
38. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE and Maitland NJ: Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 91: 1842-1850, 2004.
39. Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Scorcioni F, Candiano G, Mangiola M and Bettuzzi S: Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann NY Acad Sci 1010: S514-S519, 2003.
40. Moretti RM, Montagnani Marelli M, Mai S, Cariboni A, Scaltriti M, Bettuzzi S and Limonta P: Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res 67: 10325-10333, 2007. (Pubitemid 350070807)
41. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 12: 101-104, 2005. (Pubitemid 40090035)
42. Lee SH and Dominguez R: Regulation of actin cytoskeleton dynamics in cells. Mol Cells 29: 311-325, 2010.
43. Scott RW and Olson MF: LIM kinases: function, regulation and association with human disease. J Mol Med 85: 555-568, 2007. (Pubitemid 46870893)
44. Jordan MA and Wilson L: Microtubules as a target for anticancer durgs. Nat Rev Cancer 4: 253-265, 2004.
45. Etienne-Manneville S: Actin and microtubules in cell motility: which one is in control? Traffic 5: 470-477, 2004.
46. Eriksson JE, Dechat T, Grin B, Helfand B, Mendez M, Pallari H-M and Goldman RD: Introducing intermediate filaments: from discovery to disease. J Clin Invest 119: 1763-1771, 2009.
47. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AAG, Villette J-M, Stower MJ and Maitland NJ: Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52: 253-263, 2002.
48. Zhao Y, Yan Q, Long X, Chen X and Wang Y: Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26: 571-577, 2008.
49. Yilmaz M and Christofori G: Mechanisms of motility in metastasizing cells. Mol Cancer Res 8: 629-642, 2010.
50. Hugo H, Ackland ML, Blick T, Lawrence MG, Clemens JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383, 2007. (Pubitemid 47509716)
51. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR and Sarkar FH: miR-200 regulates PDGF-D-mediated epithelial-mesencymal transition, adhesion, and invesion of prostate cancer cells. Stem Cells 27: 1712-1721, 2009.
52. Gan Y, Shi C, Inge L, Hibner M, Balducci J and Huang Y: Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29: 4947-4958, 2010.
53. Lenferink AE, Cantin C, Nantel A, Wang E, Durocher Y, Banville M, Paul-Roc B, Marcil A, Wilson MR and O'Connor-McCourt MD: Transcriptome profiling of TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 29: 831-844, 2010.
54. Yee DS, Tang Y, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH and Zi X: The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 9: 162-175, 2010.
55. Bettuzzi S and Rizzi F: Nuclear CLU (nCLU) and the fate of the cell. Adv Cancer Res 104: 59-88, 2009.
56. Pucci S and Bettuzzi S: The shifting balance between CLU forms during tumor progression. Adv Cancer Res 104: 25-32, 2009.
57. Miyake H, Hara I, Fujisawa M and Gleave ME: The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 15: 507-517, 2006.
58. Di Cresce C and Koropatnick J: Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets 10: 555-565, 2010.